866-997-4948(US-Canada Toll Free)

Published on : Nov 06, 2015

Global leader in smart systems and printed electronics Thin Film Electronics ASA announced on Friday a partnership with major manufacturer and developer of self-medication injection systems Ypsomed Group. The companies, through this partnership, will come together to incorporate Thin Film’s NFC OpenSense technology in the YpsoMate autoinjector to improve patient self care. 

YpsoMate autoinjectors house pre-filled polymer or glass syringes, are disposable 2 step injection systems, and are triggered with the help of push on skin activation. Autoinjectors are used by patients to deliver periodic injections on themselves for ongoing management of chronic illnesses such as cardiovascular indications or rheumatoid arthritis, rendering compliance a major factor in the treatment plan of the patients. With the help of a combination of a custom mobile app and the NFC OpenSense tags, patients will receive key compliance assistance such as injection reminders, adherence history, refill instructions, usage guidelines, and authentication. On the other hand, doctors too will be able to keep a track of whether or not the patients have been complying with the daily requirements of self medication. 

The NFC OpenSense tags are thin and flexible labels that can identify the condition of the patient before as well as after the YpsoMate autoinjector has been used. The tags can also deliver content to the patients wirelessly through just the tap of a smartphone and the record the interactions of the patient with the device in the cloud. Each NFC OpenSense tag has a unique identifier that allows it to track each YpsoMate Smart to an individual item level. Moreover, even after the factory seal is broken, the tag remains active, allowing an extended dialogue among doctors, patients, and brands. 

Chief executive officer of Ypsomed Simon Michel said that as a leader in quality and innovation, Ypsomed is always seeking for better ways to enhance its product offering.